Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case
This article describes a case of successfully used tocilizumab (interleukin 6 receptors monoclonal antibodies) in a two-year patient with severe systemic juvenile idiopathic arthritis resistant to oral and parenteral glucocorticoids, nonsteroidal anti-inflammatory drugs, and methotrexate. Just after...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Union of pediatricians of Russia
2016-11-01
|
| Series: | Педиатрическая фармакология |
| Subjects: | |
| Online Access: | https://www.pedpharma.ru/jour/article/view/1447 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849395861514092544 |
|---|---|
| author | E. I. Alekseeva S. I. Valieva T. M. Bzarova R. V. Denisova T. V. Sleptsova O. L. Lomakina A. M. Chomakhidze |
| author_facet | E. I. Alekseeva S. I. Valieva T. M. Bzarova R. V. Denisova T. V. Sleptsova O. L. Lomakina A. M. Chomakhidze |
| author_sort | E. I. Alekseeva |
| collection | DOAJ |
| description | This article describes a case of successfully used tocilizumab (interleukin 6 receptors monoclonal antibodies) in a two-year patient with severe systemic juvenile idiopathic arthritis resistant to oral and parenteral glucocorticoids, nonsteroidal anti-inflammatory drugs, and methotrexate. Just after the first injection of tocilizumab, fever and pain ceased, morning stiffness decreased significantly; laboratory disease activity indices normalized by the 4th week of drug use; by the 16th week inflammatory changes in the joints regressed completely, the disease entered its inactive phase. After using tocilizumab, remission duration was 20 months for articular syndrome and systemic manifestations. No adverse reactions have been registered. |
| format | Article |
| id | doaj-art-9e4fa09829bf4dbabbd00d6090e2ddd7 |
| institution | Kabale University |
| issn | 1727-5776 2500-3089 |
| language | Russian |
| publishDate | 2016-11-01 |
| publisher | Union of pediatricians of Russia |
| record_format | Article |
| series | Педиатрическая фармакология |
| spelling | doaj-art-9e4fa09829bf4dbabbd00d6090e2ddd72025-08-20T03:39:29ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892016-11-0113439039410.15690/pf.v13i4.16131428Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical CaseE. I. Alekseeva0S. I. Valieva1T. M. Bzarova2R. V. Denisova3T. V. Sleptsova4O. L. Lomakina5A. M. Chomakhidze6Scientific Center of Children’s Health; Sechenov First Moscow State Medical UniversityScientific Center of Children’s Health; Pirogov Russian National Research Medical UniversityScientific Center of Children’s Health; Sechenov First Moscow State Medical UniversityScientific Center of Children’s HealthScientific Center of Children’s HealthScientific Center of Children’s HealthScientific Center of Children’s HealthThis article describes a case of successfully used tocilizumab (interleukin 6 receptors monoclonal antibodies) in a two-year patient with severe systemic juvenile idiopathic arthritis resistant to oral and parenteral glucocorticoids, nonsteroidal anti-inflammatory drugs, and methotrexate. Just after the first injection of tocilizumab, fever and pain ceased, morning stiffness decreased significantly; laboratory disease activity indices normalized by the 4th week of drug use; by the 16th week inflammatory changes in the joints regressed completely, the disease entered its inactive phase. After using tocilizumab, remission duration was 20 months for articular syndrome and systemic manifestations. No adverse reactions have been registered.https://www.pedpharma.ru/jour/article/view/1447tocilizumabjuvenile idiopathic arthritischildren |
| spellingShingle | E. I. Alekseeva S. I. Valieva T. M. Bzarova R. V. Denisova T. V. Sleptsova O. L. Lomakina A. M. Chomakhidze Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case Педиатрическая фармакология tocilizumab juvenile idiopathic arthritis children |
| title | Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case |
| title_full | Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case |
| title_fullStr | Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case |
| title_full_unstemmed | Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case |
| title_short | Treating Systemic Juvenile Idiopathic Arthritis with Tocilizumab: Clinical Case |
| title_sort | treating systemic juvenile idiopathic arthritis with tocilizumab clinical case |
| topic | tocilizumab juvenile idiopathic arthritis children |
| url | https://www.pedpharma.ru/jour/article/view/1447 |
| work_keys_str_mv | AT eialekseeva treatingsystemicjuvenileidiopathicarthritiswithtocilizumabclinicalcase AT sivalieva treatingsystemicjuvenileidiopathicarthritiswithtocilizumabclinicalcase AT tmbzarova treatingsystemicjuvenileidiopathicarthritiswithtocilizumabclinicalcase AT rvdenisova treatingsystemicjuvenileidiopathicarthritiswithtocilizumabclinicalcase AT tvsleptsova treatingsystemicjuvenileidiopathicarthritiswithtocilizumabclinicalcase AT ollomakina treatingsystemicjuvenileidiopathicarthritiswithtocilizumabclinicalcase AT amchomakhidze treatingsystemicjuvenileidiopathicarthritiswithtocilizumabclinicalcase |